Genetic variants in genes such as SLC6A4 (SERT), DRD2 (dopamine receptor), PRDM16 or CYP1A2, and GNB3 have been associated with a modified therapy outcome with triptans in migraine and cluster headache, respectively. This evidence concerns the gene PRDM16 and Cluster headache.